Clinical trials: Morbidity
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at 5 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm…
- Trial name
- CONSCIOUS-2 (NCT00558311)
- Testing
- Clazosentan
- Where
- 117 sites in United States, Australia and 27 more
- Volunteers
- 1,157 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy, Chronic Disease
A Urine Sample Collection Study in Apparently Healthy Adults and Adults With Chronic, Stable Morbidities
The objective of this study is collect urine samples from healthy adult subjects and subjects with stable chronic morbidities for future testing to serve as controls and establish reference ranges in the development of new…
- Trial name
- NCT05853016
- Testing
- Urine collection for NEPHROCLEAR CCL14 Test
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Astute Medical, Inc.
Chronic Kidney Disease, Left Ventricular Hypertrophy
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
To evaluate the effects of paricalcitol capsules on cardiac structure and function over 48 weeks in patients with Stage 3/4 chronic kidney disease (CKD) who had left ventricular hypertrophy (LVH).
- Trial name
- PRIMO (NCT00497146)
- Testing
- paricalcitol
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 227 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetes Mellitus, Non-Insulin-Dependent
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
The primary objectives of the ORIGIN study were: To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired…
- Trial name
- ORIGIN (NCT00069784)
- Testing
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), reusable pen device for insulin injection
- Where
- 40 sites in United States, Argentina and 38 more
- Volunteers
- 12,537 people
- Sponsor
- Sanofi
Heart Failure With Reduced Ejection Fraction
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =< 35%).
- Trial name
- PARADIGM-HF (NCT01035255)
- Testing
- LCZ696 200 mg BID, Enalapril 10 mg BID
- Where
- 1,031 sites in United States, Argentina and 45 more
- Volunteers
- 8,442 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.
- Trial name
- NCT00268216
- Testing
- Salmeterol 50mcg/ Fluticasone Propionate 500mcg
- Where
- 459 sites in United States, Argentina and 42 more
- Volunteers
- 6,228 people
- Sponsor
- GlaxoSmithKline
Chronic Renal Anemia
A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
This 2 arm safety study will compare the outcome with respect to a composite endpoint of all-cause mortality and non-fatal cardiovascular events (myocardial infarction, stroke) in CKD participants either on dialysis or not…
- Trial name
- NCT00773513
- Testing
- Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta
- Where
- 196 sites in Argentina, Australia and 25 more
- Volunteers
- 2,825 people
- Sponsor
- Hoffmann-La Roche
Genetics of Drug Metabolism
Pharmacogenomic Testing Of the Elderly To Reduce Morbidity
The goal of the POETRY Registry is to determine whether data from Pharmacogenomic (PGx) Testing for elderly and disabled patients can help physicians manage patient medication regimens and assess if the testing has an effect on…
- Trial name
- POETRY (NCT02095769)
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 280,000 people
- Sponsor
- General Genetics Corporation
Congestive Heart Failure
European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure
The purpose of this study is to assess the efficacy, tolerability and safety of dronedarone versus placebo in patients with symptomatic congestive heart failure (CHF) and left ventricular dysfunction (LVD) when added to evidence…
- Trial name
- ANDROMEDA (NCT00696631)
- Testing
- Dronedarone (SR33589)
- Where
- 6 sites in Denmark, Hungary and 4 more
- Volunteers
- 653 people
- Sponsor
- Sanofi
Urinary Tract Infections
Morbidity Rate for UTI Through Use of PCR-Based Diagnosis and Management
This retrospective study is to determine if the use of PCR for detection and identification of pathogens in UTI along with antimicrobial susceptibility information, affords more efficacious treatment of UTI, as compared to…
- Trial name
- NCT04108910
- Testing
- Guidance UTI
- Volunteers
- 66,381 people
- Sponsor
- Pathnostics
Congestive Heart Failure
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)
A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function
- Trial name
- NCT00634712
- Testing
- Candesartan
- Volunteers
- 734 people
- Sponsor
- AstraZeneca
Giant Cell Tumor of Bone
A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
This is a retrospective observational real-world study, which evaluates the efficacy and safety of denosumab and non-denosumab therapies in the treatment of Chinese populations of surgically unsalvageable or severe post-surgery…
- Trial name
- NCT05402865
- Testing
- Denosumab
- Where
- 3 sites in China
- Volunteers
- 301 people
- Sponsor
- Shanghai JMT-Bio Inc.
Essential Hypertension
Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension
The purpose of this study is: To evaluate the effects of NEBILET®(Nebivolol), used as monotherapy or in combination with other antihypertensive agents, in the control of BP and in the metabolic profile of patients with essential…
- Trial name
- BENEFIT (NCT03847350)
- Where
- South Korea
- Volunteers
- 3,250 people
- Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.
- Trial name
- ENSEMBLE (NCT04505722)
- Testing
- Ad26.COV2.S
- Where
- 225 sites in United States, Argentina and 6 more
- Volunteers
- 44,325 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Polypharmacy Patients
Assessment of a Novel Algorithm System for Polypharmacy Patient Medication Safety and Consultation
The aim of this study is to determine if insights based on the analysis of historical data of multidrug patients' electronic health records, by a novel system and algorithm, is noninferior to a clinical pharmacist analysis and…
- Trial name
- NCT05589870
- Testing
- Multi-drug analysis of polypharmacy treatment
- Where
- Israel
- Volunteers
- 91 people
- Sponsor
- MDI Health
Heart Failure
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack.
- Trial name
- EMPHASIS-HF (NCT00232180)
- Testing
- Eplerenone
- Where
- 307 sites in United States, Argentina and 27 more
- Volunteers
- 2,743 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Heart Disease
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
This study will evaluate the potential of RO4607381 to reduce cardiovascular morbidity and mortality in stable coronary heart disease patients with recent Acute Coronary Syndrome (ACS) and evaluate the long term safety profile of…
- Trial name
- NCT00658515
- Testing
- Dalcetrapib (RO4607381), Evidence-based medical care for Acute Coronary Syndrome
- Where
- 1,089 sites in United States, Argentina and 27 more
- Volunteers
- 15,871 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Disease, Chronic Obstructive
Airflow Limitation in Cardiac Diseases in Europe
This is a cross-sectional, observational study, investigating the point prevalence of Airflow Limitation in current or former smokers with established ischemic heart disease.
- Trial name
- ALICE (NCT01485159)
- Testing
- Spirometry
- Where
- 15 sites in Belgium, France and 7 more
- Volunteers
- 3,000 people
- Sponsor
- GlaxoSmithKline